Article
Oncology
Yiqing Huang, Yu Yang Soon, Folefac Aminkeng, Sen Hee Tay, Yvonne Ang, Adrian C. L. Kee, Boon Cher Goh, Alvin S. C. Wong, Ross A. Soo
Summary: This study analyzed IrAEs in NSCLC patients receiving immunotherapy, and found that concomitant chemotherapy use, higher BMI, and the presence of EGFR mutation were significant predictors for IrAEs.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Gastroenterology & Hepatology
Samuel Chuah, Joycelyn Lee, Yuan Song, Hyung-Don Kim, Martin Wasser, Neslihan A. Kaya, Kyunghye Bang, Yong Joon Lee, Seung Hyuck Jeon, Sheena Suthen, Shamirah A'Azman, Gerald Gien, Chun Jye Lim, Camillus Chua, Sharifah Nur Hazirah, Hong Kai Lee, Jia Qi Lim, Tony K. H. Lim, Joe Yeong, Jinmiao Chen, Eui-Cheol Shin, Salvatore Albani, Weiwei Zhai, Changhoon Yoo, Haiyan Liu, Su Pin Choo, David Tai, Valerie Chew
Summary: This study identifies immune cell subsets associated with response and irAEs in HCC patients receiving anti-PD-1 therapy and proposes a new combination immunotherapy for enhanced response without exacerbating adverse events.
JOURNAL OF HEPATOLOGY
(2022)
Article
Oncology
Eniko Sebestyen, Nora Major, Levente Bodoki, Attila Makai, Ingrid Balogh, Gabor Toth, Zsuzsanna Orosz, Peter Arkosy, Attila Vasko, Katalin Hodosi, Zoltan Szekanecz, Eva Szekanecz
Summary: This study assessed patients with malignancies who underwent anti-PD-1 treatment at the University of Debrecen, Clinical Center. The study found that immune-related adverse events (irAEs) may be associated with the number of treatment cycles and the type of treated malignancy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Benjamin Mueller, Anne Baerenwaldt, Petra Herzig, Alfred Zippelius, Lara Valeska Maul, Viviane Hess, David Koenig, Heinz Laeubli
Summary: This study characterized the peripheral immune cell subsets in patients receiving anti-PD-1 monotherapy and dual immune receptors blockade, and found differences in CD8(+) T cell subsets between patients with severe immune-related side effects and those with mild irAEs. These changes may serve as biomarkers for early diagnosis of irAEs in the future.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Marianne Gazzano, Christophe Parizot, Dimitri Psimaras, Aurore Vozy, Marine Baron, Baptiste Abbar, Vincent Fallet, Elena Litvinova, Anthony Canellas, Cristina Birzu, Valerie Pourcher, Mehdi Touat, Nicolas Weiss, Sophie Demeret, Damien Roos-Weil, Jean-Philippe Spano, Celeste Lebbe, Joe-Elie Salem, Jacques Cadranel, Baptiste Hervier, Guy Gorochov, Amelie Guihot
Summary: Immune checkpoint inhibitors have greatly improved the treatment of solid and hematologic malignancies, but can also lead to immune related adverse events (irAEs) that are difficult to diagnose. This study developed a flow cytometry assay to measure the occupancy of PD-1 receptors and guide the diagnosis of irAEs. The results suggest that monitoring ICI occupancy using flow cytometry can be useful in diagnosing and managing irAEs in patients treated with monoclonal ICI.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Lin Zhou, Xin Wei
Summary: This study comprehensively illustrated the clinical characteristics, diagnosis, and management of immune checkpoint inhibitor (ICI)-related ocular immune-related adverse events (irAEs) in lung cancer patients based on 79 reported cases. Ophthalmoplegia, uveitis, and dry eye were the most common ICI-related ocular irAEs, with ophthalmoplegia having the highest mortality rate. Ethnicity and the type of ICIs significantly influenced the distribution of ocular irAEs, with early onset and worse prognosis features observed in ICI-related ophthalmoplegia.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Mingyue Liu, Xu Wang, Xuexiang Du, Wei Wu, Yan Zhang, Peng Zhang, Chunxia Ai, Martin Devenport, Juanjuan Su, Musleh M. Muthana, Lishan Su, Yang Liu, Pan Zheng
Summary: Immune checkpoint inhibitors (ICIs) like nivolumab and ipilimumab show both antitumor responses and severe immune-related adverse events (irAEs), but treating irAEs without affecting the immunotherapeutic effect of ICIs remains a challenge. The use of abatacept to treat irAEs risks reducing the efficacy of anti-CTLA-4 immunotherapy. However, mutants of CTLA-4-Ig that bind to B7-1 and B7-2 can effectively treat irAEs without affecting cancer immunotherapy, making belatacept a potential drug to abrogate irAEs while preserving the therapeutic efficacy of CTLA-4-targeting ICIs.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Review
Endocrinology & Metabolism
Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
Summary: Immune checkpoint inhibitors are effective in cancer treatment, but can lead to immune-related adverse events, including thyroid dysfunction. Early prediction and detection of these events are crucial, as they can serve as prognostic markers and indicators of treatment response.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Zhaodan Xin, Liting You, Feifei Na, Jin Li, Min Chen, Jiajia Song, Ling Bai, Jie Chen, Juan Zhou, Binwu Ying
Summary: In this study, the researchers identified several immunogenetic variants associated with immune-related adverse events (irAEs) and irAEs-free survival in patients treated with PD-1/PD-L1 inhibitors, which could serve as potential predictive biomarkers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Melissa L. Bastacky, Hong Wang, Dylan Fortman, Zahra Rahman, Gerard P. Mascara, Timothy Brenner, Yana G. Najjar, Jason J. Luke, John M. Kirkwood, Hassane M. Zarour, Diwakar Davar
Summary: This study of 190 metastatic melanoma patients treated with single-agent anti-PD-1 ICI therapy found that 60% experienced at least one immune-related adverse event (irAEs), with irAE occurrence significantly associated with response to anti-PD-1 therapy. Patients with multiple irAEs exhibited distinct patterns, and obesity was distinctly associated with irAE development, while age and gender showed no significant association.
FRONTIERS IN ONCOLOGY
(2021)
Article
Dermatology
Henry T. Quach, Douglas B. Johnson, Nicole R. LeBoeuf, Jeffrey P. Zwerner, Anna K. Dewan
Summary: ICIs can lead to a variety of cutaneous adverse events, ranging from common eczematous and morbilliform dermatoses to less common psoriasiform dermatoses and bullous disorders. The immunologic mechanism of ICIs may also cause rheumatologic adverse reactions with cutaneous manifestations, which can typically be managed with steroids. As ICIs become more widely prescribed, dermatologists will play a crucial role in accurately diagnosing and treating these toxicities to ensure favorable outcomes for patients.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Review
Oncology
Chenrui Tian, Xiaohui Wang, Sheng Zhang
Summary: Esophageal cancer is a prevalent disease with poor prognosis. Conventional treatments include surgery, chemotherapy, and radiotherapy, but the risk of relapse and metastasis remains high. Immune checkpoint inhibitors have emerged as a transformative treatment option for esophageal cancer, especially when combined with chemotherapy or radiotherapy.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Oncology
Xiaoyun Zhang, Shuo Xu, Jiaqi Wang, Yalei Lv, Na Wang, Ruixue Lai, Ziyue Sha, Qun Zhao, Zhanjun Guo
Summary: The occurrence of immune-related adverse events (irAEs) in patients with advanced gastric cancer treated with anti PD-1 antibodies may contribute to improved prognosis.
Article
Immunology
Linyang Gan, Huan Chen, Xiaowei Liu, Li Zhang
Summary: This study investigated the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor therapy and reported the clinical features, management, and outcomes of ophthalmic irAEs. Medical records of 962 patients who received ICI therapy were retrospectively reviewed, and 248 patients (25.8%) experienced irAEs. The first-year incidences of total irAEs and ophthalmic irAEs were 23.5% and 1.1% respectively. The most common ICI received was pembrolizumab (38.8%).
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Orthi Shahzad, Nicola Thompson, Gerry Clare, Sarah Welsh, Erika Damato, Philippa Corrie
Summary: Ocular immune-related adverse events associated with checkpoint inhibitors in cancer treatment are rare but require timely intervention to prevent permanent vision loss. Anterior uveitis is the most common ocular side effect requiring intervention, and a simple algorithm can help clinicians manage patients efficiently. Local interventions may be effective in avoiding systemic corticosteroids and continuing CPI therapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Ophthalmology
Michel M. Sun, Ralph D. Levinson, Artur Filipowicz, Stephen Anesi, Henry J. Kaplan, Wei Wang, Debra A. Goldstein, Sapna Gangaputra, Robert T. Swan, H. Nida Sen, Lynn K. Gordon
OCULAR IMMUNOLOGY AND INFLAMMATION
(2020)
Article
Ophthalmology
Golnoush Mahmoudinezhad, Vahid Mohammadzadeh, Navid Amini, Veronica Toriz, Mohammad Pourhomayoun, Sepideh Heydarzadeh, Apoorva Mylavarapu, Esteban Morales, Joseph Caprioli, Kouros Nouri-Mahdavi
Summary: This study compared local ganglion cell inner plexiform layer (GCIPL) thickness measurements between two OCT devices and found that they are highly correlated at the superpixel level but not interchangeable. Differences in measurements between the devices are influenced by the location and thickness of superpixels.
OPHTHALMOLOGY GLAUCOMA
(2021)